Khushi Quadri

Khushi Quadri

Auto-generated profile, based on publicly available information

Khushi Quadri

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, DL, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in iLIVER
Verified
Journal Article
Open access
PYPooja Yadav
Pooja Yadav
KQKhushi Quadri
Khushi Quadri
RKRenu Kadian
Renu Kadian
AWAafrin Waziri
Aafrin Waziri
PAPankaj Agrawal
Pankaj Agrawal
Md. Sabir AlamMd. Sabir Alam
Md. Sabir Alam
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread and potentially severe liver condition characterized by abnormal fat accumulation in the liver unrelated to alcohol consumption. According to the World Health Organization, MASLD is the most prevalent liver disease globally, it affects approximately 25% of the world’s population, nearly two billion individuals. This staggering prevalence underscores the urgent need for effective and safe therapeutic approaches to address this escalating global health concern. Natural products have emerged as promising candidates for preventing and treating MASLD in recent years because of their diverse bioactive compounds and minimal side effects. Well-known natural products such as curcumin, resveratrol, green tea polyphenols, and silymarin exhibit notable hepatoprotective effects by influencing lipid metabolism, mitigating oxidative stress, and reducing inflammation. Ongoing research highlights the potential of phytochemicals from traditional medicinal plants, such as Phyllanthus and Salvia, in ameliorating liver steatosis and fibrosis. These natural products demonstrate the capacity to impede fibrogenesis by interfering with hepatic stellate cell activation, which is pivotal in liver fibrosis development. Recent studies underscore the significance of natural products in modulating the gut–liver axis, where they restore balance to the gut microbiota and enhance intestinal barrier function, which slows the progression of MASLD. Moreover, advancements in nanotechnology facilitate the targeted delivery of natural product-derived compounds, which enhances their bioavailability and therapeutic efficacy. Harnessing the potency of natural products offers a promising avenue for developing novel, safer therapies for MASLD and addressing a critical global health concern with far-reaching implications for public well-being.

23 October 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
PKPuja Kumari
Puja Kumari
KQKhushi Quadri
Khushi Quadri
RKRenu Kadian
Renu Kadian
SMSaloni Mishra
Saloni Mishra
AWAafrin Waziri
Aafrin Waziri
Md. Sabir AlamMd. Sabir Alam
Md. Sabir Alam
The green synthesis of silver nanoparticles (AgNPs) has recently gained prominence as a sustainable and eco-friendly alternative to conventional physical and chemical methods. Utilizing biological entities such as plant extracts, bacteria, fungi, and biomolecules, the method acts by both reducing and stabilizing mechanisms. It does not use any harmful chemical substances, thus proving to be eco-friendly. Green-synthesized AgNPs exhibit enhanced biocompatibility, stability, and targeted delivery of the drug due to the use of naturally derived surface capping agents. These unique characteristics allow selective interference with cancer cells. The mechanism involved is the generation of reactive oxygen species (ROS), the induction of apoptosis, DNA damage, and cell cycle arrest. Green AgNPs also possess broad-spectrum antimicrobial, catalytic, antiparasitic, and anti-inflammatory properties, supporting the fact that they can be utilised in biomedical fields such as drug delivery, bioimaging, biosensing, tissue engineering, and regenerative medicine. Recent advancements have focused on controlling NP size, shape, and surface functionality to maximize efficacy while simultaneously minimizing cytotoxicity. This review provides a comprehensive analysis of the latest green synthesis strategies, their characterizations, and the molecular mechanisms by which they exert anticancer effects. Recent patents highlight the clinical potential of AgNPs in cancer therapy. US Patent 12201650 (2025) describes green synthesis using Caralluma sinaica, while other patents (WO2007001453, US7462753) outline adaptable biomedical formulations. Studies on biogenic AgNPs also show significant tumor inhibition and selective cytotoxicity against cancer cells. Furthermore, the article discusses current biomedical applications and critically evaluates the limitations, such as reproducibility, toxicity concerns, and scalability for clinical translation. Addressing these challenges is essential for the integration of green AgNPs into mainstream cancer therapeutics. The convergence of nanotechnology and biologically derived synthesis opens promising avenues for the development of safe, effective, and environmentally sustainable medical innovations.

22 October 2025 in Recent Advances in Anti-Infective Drug Discovery
Verified
Journal Article
Closed access
PDF file
KQKhushi Quadri
Khushi Quadri
LRLaxmi Rani
Laxmi Rani
PMPooja Mathur
Pooja Mathur
Bacterial conjunctivitis is a common eye infection caused by bacteria, posing significant treatment challenges due to rising antibiotic resistance and the limitations of traditional therapies. Standard treatments, including topical antibiotics, often suffer from issues such as poor bioavailability, limited effectiveness, and patient adherence. Nanotechnology offers an innovative approach, providing potential solutions for more effective drug delivery, diagnostics, and therapeutic interventions. The objective of this study is to explore the role of nanotechnology in improving the management of bacterial conjunctivitis. Specifically, it examines how nanostructured drug carriers, such as nanoparticles, nanogels, and liposomes, can enhance ocular drug delivery and therapeutic outcomes. A key focus is on the influence of the hydrodynamic radius (Rh) in optimizing stability, solubility, and bioavailability. Nanotechnology has shown promise in improving the delivery of drugs for bacterial conjunctivitis by enhancing ocular penetration and prolonging the release of active agents. The hydrodynamic radius (Rh) of nanoparticles plays a critical role in stabilizing the colloidal structure of the formulation, preventing aggregation and sedimentation. Furthermore, optimizing Rh can increase the surface area-to-volume ratio, which is beneficial for improving the solubility of poorly soluble drugs, thereby enhancing their bioavailability. Nanotechnology- based systems can also enable the development of diagnostic tools, such as nanosensors, capable of quickly and accurately detecting bacterial pathogens, facilitating timely, targeted treatments and reducing unnecessary use of broad-spectrum antibiotics. The precise control of nanoparticle Rh enhances drug stability, bioavailability, and sustained release, ultimately improving patient compliance and therapeutic efficacy. The future of bacterial conjunctivitis treatment is promising, with further research focused on optimizing nanoparticle characteristics such as size, surface modification, and targeted drug delivery. However, challenges remain, particularly concerning the safety of nanoparticles, including potential risks to ocular tissues and long-term effects. Continued research, including in vitro and in vivo studies as well as clinical trials, is essential to establish the safety and clinical viability of these nanotechnology-based systems. With further advancements, nanotechnology could revolutionize treatment strategies for bacterial conjunctivitis, offering more targeted, patient-centered, and effective solutions for managing ocular infections and combating antibiotic resistance.

3 December 2025
Verified
Book Chapter
Closed access
PAPoonam Arora
Poonam Arora
KQKhushi Quadri
Khushi Quadri
DEDeepti
Deepti